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In this cross-sectional study, we sought to describe cognitive and neuroimaging profiles
of Memory clinic patients with Mild Cognitive Impairment (MCI). 51 MCI patients and
51 controls, matched on age, sex, and socio-economic status (SES), were assessed
with an extensive neuropsychological test battery that included a measure of intelligence
(General Ability Index, “GAI,” from WAIS-IV), and structural magnetic resonance imaging
(MRI). MCI subtypes were determined after inclusion, and z-scores normalized to our
control group were generated for each cognitive domain in each MCI participant. MR-
images were scored by visual rating scales. MCI patients performed significantly worse
than controls on 23 of 31 cognitive measures (Bonferroni corrected p = 0.001), and on
8 of 31 measures after covarying for intelligence (GAI). Compared to nonamnestic MCI
patients, amnestic MCI patients had lower test results in 13 of 31 measures, and 5 of 31
measures after co-varying for GAI. Compared to controls, the MCI patients had greater
atrophy on Schelten’s Medial temporal lobe atrophy score (MTA), especially in those
with amnestic MCI. The only structure-function correlation that remained significant after
correction for multiple comparisons was the MTA—long delay recall domain. Intelligence
operationalized as GAI appears to be an important moderator of the neuropsychological
outcomes. Atrophy of themedial temporal lobe, based onMTA scores, may be a sensitive
biomarker for the functional episodic memory deficits associated with MCI.
Keywords: MCI, intelligence, memory clinic patients, cognitive dysfunction, brain pathology, structural magnetic
resonance imaging, neuropsychological functioning, neuropsychological tests
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INTRODUCTION
The term “Mild Cognitive Impairment” (MCI) is currently
understood as a clinical condition characterized by reduction in
memory and/or other cognitive processes not severe enough to
meet the criteria for dementia, but more pronounced than the
cognitive decline associated with normal aging (Reisberg and
Ferris, 1982; Petersen et al., 1997, 1999; Reisberg et al., 2008; Geda
and Nedelska, 2012). According to the Petersen criteria, MCI is
operationalized as objective impairment on neuropsychological
tests, in combination with intact general cognitive functioning
and activities of daily living (Petersen et al., 1999). Initially,
MCI was constructed as a transition stage between nonimpaired
cognitive aging and Alzheimer’s disease. Since then the initial
focus on memory impairment in the MCI criteria has expanded.
The 2004 revised criteria further classified MCI into “amnestic”
and “nonamnestic” subtypes (Petersen, 2004; Winblad et al.,
2004). When a diagnosis of MCI is established, its subtype
is defined by the results of the individuals neuropsychological
profile. In amnestic MCI, the profiles indicates deficit within
the memory domain. Conversely, nonamnestic MCI indicates
intact memory, but impaired function in other domains for
instance working memory or executive function (Petersen et al.,
1997, 1999; Collie and Maruff, 2002; Collie et al., 2002; Boeve
et al., 2003; Lopez et al., 2003, 2006; Winblad et al., 2004;
Petersen and Knopman, 2006; Petersen and Negash, 2008).
There is a lack of studies that describe cognitive profiles of
amnestic and nonamnestic MCI patients diagnosed in a memory
clinic by national guidelines. Knowledge about the individuals
neuropsychological profiles has clinical and prognostic value,
since patients with amnestic MCI, especially with multi-domain
cognitive deficits, are more likely to progress more rapidly to
dementia (Arnáiz et al., 2001; Bozoki et al., 2001; Tuokko et al.,
2003; Luis et al., 2004). In addition to prognosis, knowledge of
functional strengths and weaknesses are important for potential
treatment, interventions and guidance for caregivers (Ten Kate
et al., 2017). New clinical criteria for the diagnosis of Alzheimer’s
disease recommend the use of biomarkers (e.g., structural brain
imaging, and cerebrospinal fluid analyses) also in patients with
MCI (Dubois et al., 2007; Albert et al., 2011; Jack et al., 2011;
McKhann et al., 2011). Clinical markers of MCI include cognitive
function assessed by neuropsychological tests as described above,
and signs of structural brain pathology on magnetic resonance
imaging (MRI) (Petersen and Negash, 2008; Jak et al., 2009).
Rog and Fink (2013) recommended that cognitive assessment
in MCI should include all major neuropsychological domains
(i.e., attention, working memory, visual and verbal learning and
memory, processing speed, and executive function) and ideally
also an estimate of general cognitive ability. The aging brains’
ability to tolerate structural damage relates to the resilience,
or “reserve,” of the brain (Stern, 2013). General cognitive
ability is an estimate of an individual’s ability prior to the
onset of a pathological process, a premorbid function. The
notion of “cognitive reserve” as a mediator of structure-function
relationship between brain and cognition in aging is well-
established (Katzman et al., 1988; Stern, 2002; Robertson, 2013).
Intelligence can be considered a proxy for cognitive reserve
(Richards and Deary, 2005; Osone et al., 2015). Intelligence
is usually assessed with structured psychometric tests. One
of the most widely used test batteries worldwide is the
Wechsler Adult Intelligence scale—fourth edition (WAIS-IV).
WAIS-IV produces a composite score that represents general
intellectual ability: The Full Scale Intelligence Quotient (IQ),
which includes the following indexes: Verbal comprehension,
Perceptual reasoning, Working Memory, and Processing speed.
However, a problem of using Full Scale IQ as a measure of
cognitive reserve inMCI patients is that this composite score also
includes the domains of Working Memory and Processing speed
that are vulnerable to aging in general (Schaie, 1994), and MCI in
particular (Salthouse and Meinz, 1995). This may result in lower
scores on Full Scale IQ in patients with MCI than nonimpaired
individuals, without the intellectual ability per se being reduced.
WAIS-IV also include a composite IQ score that consist only
of the Verbal comprehension subtests and Perceptual reasoning
subtests: General Ability Index (GAI), resulting in a measure
of general ability that is not sensitive to the influence of the
working memory- and processing speed abilities (Tulsky et al.,
2001). Hence, the GAI is a measure of IQ not including subtests
of cognitive proficiency, and may therefore be a better measure
of intellectual ability or cognitive reserve than Full scale IQ in a
clinical group of patients with MCI.
Most research in this field has been performed with functional
MRI, since fMRI incorporates both structural localization and to
some degree a measure of function in one examination. However,
the most readily available methods in clinical use for evaluating
brain structure-function relationships are neuropsychological
tests and semi-quantitative scoring systems based on visual
reading of MRI. Several radiological scoring systems for clinically
evaluating brain pathology markers related to dementia exist
(Ferreira et al., 2015, 2016; Rhodius-Meester et al., 2017).
Temporal lobe atrophy is mainly evaluated by the medial
temporal lobe atrophy score (MTA) (Scheltens et al., 1995).
The amnestic MCI subtype, often regarded as prodromal
to Alzheimer’s disease (AD), is typically associated with
hippocampal atrophy assessable by the MTA score, and memory
impairment (Petersen and Morris, 2005). Other evaluation tools
like the Posterior Atrophy (PA) score (Koedam et al., 2011) and
the Global Cortical Atrophy Frontal (GCA-F) sub score (Pasquier
et al., 1996; Ferreira et al., 2016) are potential biomarkers for
early onset AD, atypical AD, and nonAD dementia (Ferreira
et al., 2017). White matter hyperintensities (WMH), depending
on lesion frequency and location, were also associated with
cognitive decline (Overdorp et al., 2014; Prins and Scheltens,
2015). A clinical scoring system for how extensive the WHI are
is the Fazekas score. This WMH scoring system is recommended
for cognitive impairment research by the Imaging Cognitive
Impairment Network group, together with the radiological
atrophy scores (Wahlund et al., 2017). Broad spectra of individual
anatomical differences, cognitive reserve, and varieties in brain
structural changes exist due to normal aging compared to that of
neurodegenerative diseases. Therefore, separating patients with
MCI from cognitively nonimpaired individuals based exclusively
on structural MRI is difficult (Gómez-Sancho et al., 2018). More
research in this field have been recommend by the Geneva Task
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Force for the Roadmap of Alzheimer’s Biomarkers (Ten Kate
et al., 2017).
In the present cross-sectional descriptive study, we aimed
to investigate and describe the differences between patients
with MCI to nonimpaired individuals on a comprehensive
neuropsychological test battery that included an estimate of
cognitive reserve (GAI) and visual radiological scoring systems.
Further, we aimed to investigate if the degree of brain pathology
identified by the clinical visual scoring systems on MRI is
correlated with the scores on neuropsychological domains of
attention, working memory, visual and verbal episodic learning
and memory, processing speed, and executive function in
patients with MCI (Rog and Fink, 2013). We hypothesized that
the MCI patients would have inferior scores on several cognitive
domains, but that GAI would moderate group differences. We
also hypothesized that greater degree of brain pathology would
be found in those with lower scores on the cognitive domains.
MATERIALS AND METHODS
Participants
The study was approved by the Norwegian Regional Committee
for medical and health research ethics, South-Eastern Health
region (no: 2013/410) and by the Department of Research at
each collaborating hospital. Fifty one patients diagnosed with
MCI were recruited from Memory clinics at four hospitals
in the South-Eastern Health Region in Norway (Sørlandet
Hospital Arendal, Telemark Hospital, Oslo University Hospital,
and Diakonhjemmet Hospital). Eligible patients with MCI were
invited to participate between August 2013 and December 2016.
The study participants were assessed with neuropsychological
tests, questionnaires for risk factors ascertainment and MRI
of the brain as specified by the Norwegian national guidelines
(NorCog) and the diagnoses of MCI were made in accordance
with the Petersen/Winblad criteria of MCI (Petersen, 2004;
Winblad et al., 2004). Classification of MCI subtypes is not done
routinely in the Memory clinics. Therefore, this classification was
performed after inclusion, according to the patients cognitive
profiles (cut-off at one neuropsychological test impaired per
domain, >1.5 SD below age- and gender-appropriate norms).
The study neuropsychologist categorized the MCI participants
into amnestic and nonamnestic MCI based on their scores on
the neuropsychological tests in the baseline assessment. Scores
more than −1.5 SD from mean compared to norms on the tasks
within the verbal and/or visual episodic memory domain were
classified as amnestic MCI. Normal scores in memory domains
combined with scores more than −1.5 standard deviation from
the mean in one or more of the other domains assessed, resulted
in categorization as nonamnesticMCI (Petersen et al., 1999, 2001;
Winblad et al., 2004).
A control group of 51 volunteers was recruited through
Sørlandet hospital’s website, local newspapers, and radio. They
were matched to the MCI group by sex, age, and socioeconomic
status (SES). SES was calculated using Hollingshead’s index of
education and occupational position, scaled from 1 (low) to
5 (high) (Hollingshead and Redlich, 1958). The participants
underwent neuropsychological assessment and brain MRI.
Exclusion criteria included head trauma with post-traumatic loss
of consciousness during the lifespan, photosensitive epilepsy, or
person unsuitable for MRI because of inserted metal or severe
claustrophobia.
See Tables 1, 2 for clinical characteristics of the groups.
Neuropsychological Assessment
A neuropsychological test battery assessed the following
cognitive domains: intelligence, attention, working memory,
processing speed, visual episodic learning/short delay recall,
visual episodic memory/long delay recall, verbal episodic
learning/short delay recall, verbal episodic memory/long delay
recall and executive functions. Standardized, internationally
renowned neuropsychological tests were applied. All tests
were administered in a fixed order by the same clinical
neuropsychologist (MMF) to all study participants. The WAIS-
IV is considered a valid and reliable battery for intelligence
testing in an adult population. It generates two general measures
of cognitive function Full scale IQ and GAI (Strauss et al.,
2006; Wechsler, 2008; Sattler and Ryan, 2009; Lezak, 2013). The
GAI was chosen as a measure of intelligence in our study. The
neuropsychological tests are listed in Table 3.
CEREBRAL MRI
Data Acquisition
Images were acquired from three different 1.5 Tesla Siemens
Aera MR Systems. Study participants were scanned with a
standardized protocol containing volumetric T1-weighted
TABLE 1 | Clinical characteristics and cognitive scores in patients with MCI










Age at assessment, years 66 (51–80) 66 (53–81) 0.849
Males/females 35/16 35/16
Education, years 13 (8–20) 14 (10–19) 0.198
Socioeconomic status 3.4 (1.1) 3.7 (1.0) 0.339
Full Scale Intelligence
Quotient WAIS-IV
96 (15) 110 (12) <0.0001
General Ability Index
(WAIS-IV)
100 (16) 114 (13) <0.0001
Verbal comprehension Index
(WAIS-IV)
100 (14) 110 (12) <0.0001
Perceptual organization
Index (WAIS-IV)
101 (17) 113 (13) <0.0001
Working memory Index
(WAIS-IV)
92 (13) 106 (17) <0.0001
Processing speed Index
(WAIS-IV)
94 (14) 104 (18) <0.0001
Mann-Whitney U-tests for nonparametric variables. The significance level is 0.05.
MCI, Mild Cognitive Impairment; SD, Standard Deviation; WAIS-IV, Wechsler Adult
Intelligence Scale, 4th edition
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TABLE 2 | Clinical characteristics and cognitive scores in patients with amnestic










Age at assessment, years 66 (53–80) 65 (51–80) 0.707
Males/females 24/11 11/5
Education, years 13 (8–20) 15 (12–18) 0.026
Socioeconomic status 3.2 (1.2) 3.9 (1.0) 0.030
Full IQ WAIS-IV 91 (13) 107 (10) <0.0001
General ability Index
(WAIS-IV)
95 (15) 112 (12) <0.0001
Verbal comprehension Index
(WAIS-IV)
95 (12) 111 (12) <0.0001
Perceptual organization
Index (WAIS-IV)
97 (17) 110 (13) 0.010
Working memory Index
(WAIS-IV)
87 (11) 102 (11) <0.0001
Processing speed Index
(WAIS-IV)
90 (14) 102 (11) <0.008
Mann-Whitney U-tests for nonparametric variables. The significance level is 0.05.
Abbreviations: MCI, Mild Cognitive Impairment; SD, Standard Deviation; WAIS-IV,
Wechsler Adult Intelligence Scale, 4th edition.
magnetization-prepared rapid gradient echo (MP-RAGE)
and fluid attenuation inversion recovery (FLAIR) sequences.
Following a pilot scan, two three-dimensional (3D) MP-RAGE
scans (sagittal, echo time 3.47ms, repetition time 2,400ms, TI
1,000ms, flip angle 8 degrees, 1.2mm resolution covering the
whole brain) and a 3D-T2 weighted fluid attenuated inversion
recovery (FLAIR) image (sagittal, echo time 335ms, repetition
time 5,000ms, TI 1,800ms, turbo factor 242, 1.2mm resolution
covering the whole brain) were performed. Total scan time was
30min.
Scoring Systems and Data Analysis
Visual radiological scoring systems were used to assess brain
pathology in the MCI patients and controls. These scales
included Scheltens Medial temporal lobe atrophy (MTA) score,
the Fazekas’s scale for WMH, Global cortical atrophy—frontal
(GCA-f) sub score and PA score (Table 4).
We evaluated the MTA, PA, and GCA-F scores on the
T1w images, and the Fazeka’s score on the FLAIR images.
For the visual rating, two experienced radiologists viewed the
images independently at separate locations. Both radiologists
were blinded toward group allocation. Reference images for all
scores were provided for both radiologists as suggested by Harper
et al. (2015). A consensus rating was held if a disagreement
existed. For all scores except the Fazekas and PA scores, both
brain hemispheres were scored and a mean score was calculated
(Schoonenboom et al., 2008; Ferreira et al., 2016). A mean score
was calculated based on both brain hemispheres for the MTA
and GCA-F (Schoonenboom et al., 2008; Ferreira et al., 2016).
The MTA score cut-offs were set at ≥1.0 for persons under 65,
TABLE 3 | Assessed cognitive domains and neuropsychological tests.
Cognitive domains Tests
Intelligence (IQ) WAIS-IV (General Ability Index/GAI)
Attention domain WAIS-IV Digit Span forward, WMS-III Spatial
Span forward, CVLT-II Trial 1, CVLT-II Trial B
Working memory domain WMS-IV Digit Span backward, WMS-III Spatial
Span backward, WMS-III Letter-Number
Sequencing
Processing speed domain WAIS-IV Coding, WAIS-IV Symbol search,
D-KEFS Color Word Interference Test 1 color




RCFT Immediate recall, WMS-III Faces I
Visual episodic memory/long
delay recall domain




WMS-III Logical Memory I, CVLT-II Total
learning, CVLT-II Short Delay Free Recall
Verbal episodic memory/ long
delay recall
Logical memory II Delayed recall, CVLT-II Long
delay free recall, CVLT Total hits
Executive functions RCFT, D-KEFS Color Word Interference Test 3
Inhibition, D-KEFS Color Word Interference test
4 Inhibit/Switching, D-KEFS Verbal Fluency
Test Letter fluency, D-KEFS Verbal Fluency Test
Category fluency, D-KEFS Verbal Fluency Test
Category switching
WAIS-IV, Wechsler Adult Intelligence Scale 4.ed, WMS-III, Wechsler Memory Scale 3.ed,
D-KEFS, Delis-Kaplan Executive Function System, RCFT, Reys Complex Figure Test,
CVLT-II, California Verbal Learning Test 2.ed.
at ≥1.5 for persons between 66 and 74 years of age, and at ≥2
for those≥ 75 years (Ferreira et al., 2017; Rhodius-Meester et al.,
2017). TheMTA score ranges from 0 to 4 (from 0= no atrophy to
4=most severe atrophy), which describes the relative size of the
hippocampus at a fixed position on T1 images. GCA-F utilized
a cutoff at ≥1.5 for all ages (Rhodius-Meester et al., 2017). The
GCA-F describes the atrophy severity of the frontal lobe, and
scores range from 0 to 3 (0 = no atrophy, 1 = mild atrophy,
2 = moderate atrophy, 3 = severe atrophy). The PA scoring
system (PA) also ranges from 0 to 3 (0 = no atrophy, 1 = mild,
2= moderate, 3= severe atrophy) and was used with the original
age cutoff for PA ≥2 (Koedam et al., 2011). Fazekas scores
categorize the nonspecific white matter hyperintensity load. The
scores range from 1 to 3 (from absent to higher white matter
lesion load depending on the location of the hyperintensities, see
footnote in Table 7); a score >1 was considered pathological for
all age groups (Fazekas et al., 1987) For all radiological scoring
systems, scores above the set cut-off values were considered
pathological.
Statistical Analysis
Statistical analyses were performed using IBM SPSS statistics,
version 23.0. The Mann-Whitney U-tests for nonparametric
variables were used to explore group differences in demographic
variables (see Tables 1, 2). Multivariate analyses of variance
within the General linear model, was used for between-group
analyses (MCI patients and controls). Covarying for sex, age, SES,
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TABLE 4 | Radiological scoring systems, range, region and age cut off.
Radiological scoring system Anatomical region/structure Range Pathological age cut off
MTA Medial temporal lobes/hippocampus 0–4 1.0 ≤ 64 years 1.5 ≥ 65–74 years ≥ 2
>75 y.
PA Parietal lobes 0–3 ≥2 for all ages.
GCA-F Frontal lobes 0–3 ≥1.5 for all ages.
FAZEKAS White matter 0–3 1 for all groups.
MTA, Scheltens Medial temporal lobe atrophy score, PA, Koedam’s posterior atrophy score. GCA-F, Passchier’s Global cortical atrophy score—frontal subscore. Fazekas, Fazekas
white matter hyperintensity (WHI) score.
and years of education in the statistical model did not change the
significance levels or frequency. The only covariate in the mixed
model was the GAI.
In order to compare cognitive performance across groups
and for the different domains, a z-score was calculated for
each domain in each participant, based on the difference from
the median score of the neuropsychological test scores in
the control group divided by the standard deviation of the
control group (z = x−mediancontrols
sd
) (Yonelinas et al., 2002).
An alpha level <0.001 was considered statistically significant
after Bonferroni-adjustment for multiple comparisons of the 31
neuropsychological outcomes. In order to reduce the number
of variables in the structure-function correlation analyses,
the neuropsychological z-scores were clustered into cognitive
domains (Rog and Fink, 2013). Each neuropsychological domain
score was correlated with each radiological score in linear
regression analysis. The linear regression analysis was performed
for each radiological score separately as a part of a hierarchic
regression analyses. Age and sex were added as covariates.
The z-score domains were analyzed with and without GAI as
a covariate in the model. For the MTA, PA, GCA-F, and Fazekas
scores, two-tailed independent sample T-tests were applied to
investigate possible differences in radiological scores between
the MCI and the control group, and between the amnestic
and nonamnestic MCI groups. For prevalence calculations, the
radiological scores were dichotomized, according to their age
cut-off. A Chi Square test was applied to investigate associations
between groups and the dichotomized scores. We used linear
regressions to model the relationship between the cognitive
domains and the radiological scores. Statistical significance for
these analyses was set to a p < 0.05.
RESULTS
Table 1 displays clinical characteristics of the study participants.
Age, gender distribution, education, and SES showed no
significant group differences. Conversely, there were significant
group differences for the results on the WAIS-IV including the
intelligence indices Full Scale IQ and GAI.
MCI Subtypes
In the MCI group, 35 participants were classified into the
amnestic subtype, while 16 participants were classified into the
nonamnestic subtype. Table 2 describes the characteristics of the
two MCI subtypes. Statistically significant differences between
the groups were found on all test variables with lowest scores in
the amnestic subtype group.
Neuropsychological Test Results
Compared to the controls, the MCI group showed lower
performance on 23 out of 31 of the cognitive outcomes
(Bonferroni adjusted p < 0.001). However, fewer results, 8 out
of 31 outcomes, remained significantly different between the two
groups when the GAI was included as a covariate to adjust for
premorbid cognitive functioning. Specifically, tasks assessing the
verbal episodic learning domain and verbal episodic memory
domain (California Verbal Learning Test-II, and Logical memory
I and II) remained significantly different between the groups.
Furthermore, significant group differences remained on a test
of executive function (Verbal Fluency Test Category Fluency)
(Table 5).
Analyses of group differences between the amnestic and
nonamnestic MCI subtypes revealed significantly inferior scores
in the amnestic group on 13 out of 31 cognitive outcomes. In the
multivariate model, with GAI as covariate, only eight measures
remained significantly different between groups (Table 6). See
Figure 1 for visual display of data.
Z-score Comparison
Figures 2, 3 show the z-scores of the MCI patients on all the
neuropsychological measures with controls as reference, on a
scale that ranges from + 0.4 standard deviations (z-score = 0.4)
to – 2.0 standard deviations (z-score = −2) from the mean, in
addition to the domain scores. Figures 2, 3 shows the results
of the amnestic and nonamnestic MCI subtype, respectively.
The amnestic MCI subtype results displayed reduced scores
(below zero) as compared to the control group on every
neuropsychological measure and for all cognitive domains, and
several measures were 2 standard deviations below the mean of
the control group. For the nonamnestic MCI subtype, some of
the results were on the positive side of zero ranging from+0.4 to
−0.9 standard deviations from the mean of the controls. Only the
domains scores were used in the structure-function analyses.
The amnestic MCI subtype results displayed reduced scores
(below zero) as compared to the control group on every
neuropsychological measure and for all cognitive domains, and
several measures were two standard deviations below themean of
the control group (Figure 2). For the nonamnestic MCI subtype,
some of the results were on the positive side of zero ranging from
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TABLE 5 | Neuropsychological test results in patients with MCI (n = 51) compared to matched controls (n = 51).








Attention WAIS-IV Digit Span forward (items correct) 8.0 (1.7) 9.4 (2.4) 0.003 0.250
WAIS-IV Digit Span forward, longest number of digits 5.4 (1.0) 6.3 (1.3) <0.0001 0.101
WMS-III Spatial Span forward (items correct) 6.4 (2.0) 7.3 (1.9) 0.025 0.624
WMS-III Spatial Span forward, longest number of items 4.6 (1.2) 5.2 (1.0) 0.005 0.203
CVLT-II Trial 1 (number of correct words) 4.0 (1.6) 5.8 (1.5) <0.0001 <0.0001
CVLT-II Trial B interference (number of correct words) 3.7 (1.6) 5.4 (2.1) <0.0001 0.001
Working memory WAIS-IV Digit Span backward (items correct) 6.7 (2.0) 8.0 (2.6) 0.011 0.645
WAIS-IV Digit Span backwards, longest number of digits 3.8 (1.0) 4.5 (1.4) 0.013 0.510
WMS-III Spatial Span backward (items correct) 5.8 (2.0) 7.6 (1.4) <0.0001 0.002
WMS-III Spatial Span backward, longest number of items 4.3 (1.0) 5.2 (0.8) <0.0001 0.004
WMS-III Letter-Number Sequencing (correct items) 7.4 (2.6) 10.1 (2.6) <0.0001 0.008
Processing speed WAIS-IV Coding (WAIS-IV) (number of items) 43.0 (14.4) 55.0 (13.4) <0.0001 0.038
WAIS-IV Symbol search (WAIS-IV) number of items 22.0 (7.5) 27.4 (8,0) 0.002 0.190
D-KEFS Color Word Interference Test 1 color naming
(seconds to complete)
40.0 (14.5) 31.6 (6.1) 0.001 0.051
D-KEFS Color Word Interference Test 2 word reading
(seconds to complete)
30.4 (15.1) 22.6 (4.2) 0.001 0.094
Visual episodic learning/ short
delay recall
Rey Complex Figure Test Immediate recall (items
remembered)
13.0 (8.0) 19.0 (6.0) <0.0001 0.011
WMS-III Faces I (items correct) 34.2 (4.7) 36.4 (4.1) 0.035 0.088
Visual episodic memory, long
delay recall
Rey Complex Figure Test Delayed Recall (items correct) 12.0 (8.0) 18.5 (5.1) <0.0001 0.002
WMS-III Faces II Delayed recall (items correct) 32.3 (4.6) 36.2 (5.7) <0.0001 0.006
Verbal episodic learning/ short
delay recall
WMS-III Logical Memory I(number of items) 27.9 (12.4) 40.5 (8.4) <0.0001 <0.0001
CVLT-II Total learning (number of correct words) 33.5 (11.0) 47.8 (10.6) <0.0001 <0.0001
CVLT-II Short Delay Free Recall (number of word) 5.5 (4.0) 10.2 (3.2) <0.0001 <0.0001
Verbal episodic memory, long
delay recall
Logical memory II Delayed recall (number of items) 13.2 (9.4) 25.3 (6.2) <0.0001 <0.0001
CVLT-II Long delay free recall (number of words
remembered)
5.2 (4.5) 10.0 (3.5) <0.0001 <0.0001
CVLT Total hits (words recognized) 12.7 (4.7) 15.1 (1.4) 0.001 0.053
Executive functions Rey Complex figure Copy trial (number of items) 31.0 (6.0) 34.5 (2.0) <0.0001 0.090
D-KEFS Color Word Interference Test 3 Inhibition
(seconds to complete)
86.0 (35.6) 60.9 (15.0) <0.0001 0.019




70.1 (18.0) <0.0001 0.002
D-KEFS Verbal Fluency Test Letter fluency (number of
words)
41.0 (17.7) 45.8 (11.8) 0.087 0.967
D-KEFS Verbal Fluency Test Category fluency (number of
words)
34.6 (11.5) 46.9 (11.1) <0.0001 <0.0001
D-KEFS Verbal Fluency Test Category switching (number
correct)
11.2 (3.7) 14.0 (3.5) 0.001 0.038
Mann Whitney U-test for nonparametric variables. *General linear model, multivariate, with General Ability Index as covariate. Bonferroni correction for multiple comparisons: significant
p-values (p < 0.001) in bold.
MCI, Mild Cognitive Impairment, CVLT-II, California Verbal Learning Test 2rd edition, WAIS-IV, Wechsler Adult Intelligence Scale 4th edition, WMS-III, Wechsler Memory Scale 3rd edition,
D-KEFS, Delis Kaplan Executive Function System.
+0.4 to −0.9 standard deviations from the mean of the controls
(Figure 3).
Neuroimaging Results
Table 7 presents the number of persons with pathological scores
on the different MRI scoring systems. Thirty one individuals
(61%) in the MCI group and 17 (33%) in the control group had
at least one pathological neuroimaging score (p = 0.010), and 17
(33%)MCI patients and 7 (14%) controls had pathological results
on more than one neuroimaging scale (p= 0.057). Hippocampal
atrophy, measured by a pathological MTA score, according to
the age cut-off, were found in 24 of the participants; 19 (54%)
in the amnestic MCI group, two (12, 5%) in the nonamnestic
MCI group and three (6%) in the control group. The MTA
score differed significantly when comparing the MCI group with
controls, when using two tailed independent t-test (p <0.0001),
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TABLE 6 | Neuropsychological test results in patients with amnestic MCI (aMCI) (n = 35) and nonamnestic MCI (naMCI) (n = 16).








Attention WAIS-IV Digit Span forward (items correct) 7.5 (1.4) 9.2 (1.7) 0.001 0.028
WAIS-IV Digit Span forward, longest number of digits 5.1 (0.8) 6.2 (0.8) <0.0001 0.012
WMS-III Spatial Span forward (items correct) 5.9 (1.9) 7.4 (1.8) 0.017 0.330
WMS-III Spatial Span forward, longest number of items 4.4 (1.1) 5.1 (1.2) 0.054 0.203
CVLT-II Trial 1 (number of correct words) 3.6 (1.5) 4.8 (1.6) 0.009 0.088
CVLT-II Trial B interference (number of correct words) 3.4 (1.4) 4.3 (2.1) 0.073 0.375
Working memory WAIS-IV Digit Span backward (items correct) 6.1 (1.7) 8.0 (1.9) 0.010 0.091
WAIS-IV Digit Span backwards, longest number of digits 3.5 (0.9) 4.4 (1.0) 0.005 0.115
WMS-III Spatial Span backward (items correct) 5.3 (1.7) 6.9 (2.0) <0.0001 0.298
WMS-III Spatial Span backward, longest number of items 4.1 (1.0) 4.9 (1.0) 0.017 0.004
WMS-III Letter-Number Sequencing (correct items) 6.5 (2.2) 9.5 (2.0) <0.0001 0.028
Processing speed WAIS-IV Coding (number of items) 38.2 (13.4) 53.2 (11.0) <0.0001 0.083
WAIS-IV Symbol search (number of items) 21.0 (7.8) 24.5 (6.3) 0.108 0.437
D-KEFS Color Word Interference Test 1 color naming
(seconds to complete)
43.9 (15.5) 31.6 (6.9) 0.002 0.168
D-KEFS Color Word Interference Test 2 word reading
(seconds to complete)
33.5 (17.0) 23.7 (6.1) 0.020 0.505
Visual episodic memory, short
delay recall
Rey Complex Figure Test Immediate recall (items
remembered)
9.9 (6.8) 19.9 (6.2) <0.0001 0.001
WMS-III Faces I (items correct) 33.4 (4.9) 35.9 (3.7) 0.061 0.239
Visual episodic memory, long
delay recall
Rey Complex Figure Test Delayed Recall (items correct) 8.9 (6.4) 19.0 (6.4) <0.0001 <0.0001
WMS-III Faces II Delayed recall (items correct) 31.6 (5.1) 33.9 (2.9) 0.101 0.229
Verbal episodic memory, short
delay recall
WMS-III Logical Memory I (number of items) 24.6 (11.9) 35.2 (10.6) 0.005 0.049
CVLT-II Total learning (number of correct words) 29.2 (9.3) 42.9 (8.7) <0.0001 0.001
CVLT-II Short Delay Free Recall (number of word) 3.8 (3.2) 9.3 (2.5) <0.0001 <0.0001
Verbal episodic memory, long
delay recall
Logical memory II Delayed recall (number of items) 10.4 (8.2) 19.3 (9.2) 0.003 0.017
CVLT-II Long delay free recall (number of words remembered) 3.5 (3.7) 8.9 (4.0) <0.0001 <0.0001
CVLT-II Total hits (words recognized) 11.7 (5.3) 14.8 (1.7) 0.016 0.441
Executive functions Rey Complex figure Copy trial (number of items) 30.3 (6.6) 33.7 (3.1) <0.0001 0.847
D-KEFS Color Word Interference Test 3 Inhibition (seconds to
complete)
97.5 (36.2) 60.6 (16.0) 0.001 0.066
D-KEFS Color Word Interference test 4 Inhibit/Switching
(seconds to complete)
112.0 (38.3) 76.1 (25.4) <0.0001 0.079
D-KEFS Verbal Fluency Test Letter fluency (number of words) 36.6 (14.1) 51.0 (15) 0.004 0.026
D-KEFS Verbal Fluency Test Category fluency (number of
words)
32.0 (10.1) 40.1 (11.1) 0.009 0.066
D-KEFS Verbal Fluency Test Category switching (number
correct)
10.3 (3.7) 13.5 (2.8) 0.002 0.081
Mann Whitney U-test for nonparametric variables. *General linear model, multivariate, with General Ability. Bonferroni correction for multiple comparisons: significant p-values (p < 0.001)
in bold.
MCI, Mild Cognitive Impairment, CVLT-II, California Verbal Learning Test 2rd edition, WAIS-IV, Wechsler Adult Intelligence Scale 4th edition, WMS-III, Wechsler Memory Scale 3rd edition,
D-KEFS. Delis Kaplan Executive Function System.
and when comparing the amnestic MCI and nonamnestic MCI
group (p = 0.006). A pathological PA score was found in
23 subjects; nine (26%) in the amnestic group, four (25%) in
the nonamnestic group and 10 (20%) in the control group
(p= 0.477). Similarly, Fazekas score was rated as pathological for
23 subjects, nine (26%) in the amnestic MCI group, four (25%)
in the nonamnestic MCI group, and 10 (20%) in the control
group (p = 0.477). A total of 11 participants had pathological
GCA-F scores; seven (20%) in the amnestic subgroup, none in
the nonamnestic subgroup and four (7%) in the control group.
The mean GCA-F score was not different between MCI patients
and controls, but there was a significant mean group difference
(p = 0.002) between the amnestic and the nonamnestic MCI
groups.
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Structure—Function Relationships
Table 8 shows the relationships between cognitive domain z-
scores and the different MRI scores in the MCI group. The
MTA score showed a significant correlation with episodic
memory/long delay recall domain score (R2 = 0.100, p = 0.043).
PA score significantly correlated with working memory domain
scores (R2 = 0.106, p = 0.043), while GCA-F score significantly
correlated with episodic learning/short delay recall domain
scores (R2 = 0.100, p= 0.036). An increased radiological atrophy
score correlated to lower performance score. Fazekas score
FIGURE 1 | The number of significantly inferior test (p < 0.001) in MCI
compared to controls or in amnestic MCI (AMCI) compared to nonamnestic
MCI (NAMCI).
showed no significant correlation with either of the cognitive
domain scores. When looking at structure-function relationships
in the control group, no correlations were found between MRI
scores and domain scores, except between the GCA score and
processing speed (p = 0.006). However, only four controls
obtained pathological GCA scores.
DISCUSSION
The study presents descriptive cross-sectional data on functional
and structural profiles of Memory clinics patients with MCI.
As expected, patients diagnosed with MCI had overall lower
performance on the neuropsychological tests and higher scores
on visually rated MRI pathology scales compared to age, gender
and SES-matched controls. Interestingly, after controlling for
intelligence assessed by GAI from the test WAIS-IV, fewer of
the neuropsychological tests remained abnormal in amnestic and
nonamnestic MCI patients. One possible interpretation of this
finding is that intelligence is a moderator of neuropsychological
performance. Another interpretation is that intelligence is a
confounder. One might argue that GAI is not a valid proxy of
cognitive reserve in an MCI population, as the results of the tests
that are included in the GAI may be reduced due to a disease
process. It is one standard deviation (SD) difference between the
MCI group and the control group. Nevertheless, the mean of all
the individual subtests in the GAI in the MCI group lies within a
normal range.
FIGURE 2 | Neuropsychological test results (SD below zero), control group-derived z-scores in patients with amnestic Mild Cognitive Impairment (aMCI, n = 35).
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Apparently, intelligence operationalized as GAI moderates
group differences on the cognitive profiles in patients with MCI
compared to controls. GAI also moderates the difference on the
profiles between patients with amnestic and nonamnestic MCI.
These findings are consistent with the literature that emphasized
low test scores do not equal pathology—obtaining multiple low
scores may or may not be a sign of a pathological condition.
Brooks and Iverson (2010) recommend utilizing knowledge of
the frequency of low test scores (base rates) to interpret reduced
performance in neuropsychological assessment in general. The
base rates of low scores vary in relation to intelligence (Ingraham
and Aiken, 1996; Crawford et al., 2007; Brooks and Iverson, 2010;
Smith and Bondi, 2013). Without a robust operationalization of,
or correction for, general cognitive function, too much emphasis
may be placed on low scores for those with low general cognitive
function, and similarly, too little on reduced test scores for those
with high general cognitive function. Having one or more scores
1,5 SD below the mean is uncommon in cognitively healthy
people with superior intelligence, and common in cognitively
healthy people with lower intelligence (Brooks et al., 2007).
If a clinician applies the same cut-off score for patients with
either low or high general cognitive ability, this may lead to
an underestimation of the cognitive deficits as “normal” in a
high cognitively functioning person, or an overestimation of the
cognitive deficits as “not normal” in a low cognitively functioning
person. This might apply to commonly used cut-off scores for
identifyingMCI. One interpretation of our data is that it might be
useful to control for intelligence by the use of GAI fromWAIS-IV,
in the interpretation of test results of patient suspected of having
MCI. This might helpminimize the risk of false positive diagnosis
in individuals with low premorbid general abilities, and false
negative diagnosis in individuals with high premorbid general
abilities.
We found that individuals with amnestic MCI had
significantly overall lower neuropsychological test performance
compared to controls, with cognitive profiles that indicate
severe functional impairment. They also had lower overall
performance compared to the nonamnestic MCI subtype. This is
in accordance with the large body of existing research on MCI,
viewing amnestic MCI as a more severe pathological condition
that diverges from cognitive changes associated with normal
aging (Petersen et al., 1997; Petersen and Morris, 2005; Smith
and Bondi, 2013).
As hypothesized, we found that the MCI group had higher
MTA scores on the visualMRI scales compared to controls, which
indicate higher prevalence of brain pathology in this patient
group. TheMCI group displayed significantly higherMTA scores
than the control group. No significant difference was found
between the groups when comparing the other visual scores.
This is in accordance with Duara et al. (2013) and Rhodius-
Meester et al. (2017) who reported MTA as the only scale
that differentiated MCI patients from controls. In the present
study, MTA scores also differentiated amnestic and nonamnestic
MCI patients, but not nonamnestic MCI patients from controls.
These results are consistent with findings of larger hippocampal
volumes in nonamnestic MCI subtypes compared to amnestic
subtypes, as reported by Vos et al. (2013) and van de Pol et al.
(2009). However, our findings are contrary to studies reporting
greater MTA scores in the nonamnestic MCI subtypes compared
to controls (van de Pol et al., 2009; Vos et al., 2013). These
different results may partly be explained by a higher average
age of the patients with nonamnestic MCI subtypes compared
to controls in previous studies. MTA score is considered age
sensitive (Rhodius-Meester et al., 2017) and more frequently
present in individuals older than 70 years of age (van de Pol et al.,
2009).
GCA-F scores indicated greater frontal lobe atrophy in the
amnestic MCI subtype compared to the nonamnestic subtype.
Whitwell et al. (2008) showed regional frontal atrophy in both
the amnestic multiple domain MCI group and the single domain
nonamnestic MCI group by using an automated segmentation
method. None of our nonamnestic participants had high GCA-
F scores. One explanation might be that the atrophy is more
localized in these individuals and therefore not severe enough to
be identified by the GCA-F scale. Our sample size of nonamnestic
patients is small, and the results may diverge in a larger study
sample.
The PA rating showed similar mean group scores between
the amnestic MCI and nonamnestic MCI subtype groups. This
finding is consistent with previous volumetric studies that found
no difference in parietal lobe volumes between subtypes of MCI
patients (Whitwell et al., 2008; van de Pol et al., 2009). Similarly,
the Fazekas scale ratings did not differentiate the subtype groups
in the present study. Previous studies of MCI patients have
found a stronger association to age than MCI subtypes using the
Fazekas scale (Bombois et al., 2007; Rhodius-Meester et al., 2017).
Hence, the lack of group differences in pathological Fazekas
score between MCI patients and controls in the present study is
in agreement with previous population studies (Schmidt et al.,
2011; Prins and Scheltens, 2015; Claus et al., 2016). The MCI-
patients with higher MTA scores had the greatest reduction in
performance on tests related to episodic memory. This finding is
in line with the large body of prior studies demonstrating that
the hippocampus is one of the neural substrates for episodic
memory formation (Ranganath et al., 2005; Nichols et al., 2006;
Lewis-Peacock and Postle, 2008).
In contrast, the frontal lobe score GCA-F correlated with
performance on the episodic learning. This is in accordance
with studies reporting that episodic learning (encoding) is
mediated by brain structures involving the prefrontal cortex
in addition to hippocampus (Nee and Jonides, 2011; Harding
et al., 2015). Although the frontal lobes is known to be
involved in executive function, the frontal lobe score GCA-F
did not correlate with performance on the executive functioning
domain scores in the MCI patients in our study. The problems
with operationalizing executive functions has been addressed
previously in a meta-analysis by Alvarez and Emory (2006), were
they examine the validity of the executive function-construct as
measured by cognitive tests in relation to frontal lobe damage.
They concluded with “inconsistent support for the historical
association between executive functions and the frontal lobes”
(Alvarez and Emory, 2006, p. 33). Recent studies has focused on
executive functions in relation to neural networks, rather than a
regional anatomical/structural frame of reference (Weiler et al.,
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FIGURE 3 | Neuropsychological test results (SD below zero), control group-derived z-scores in patients with nonamnestic Mild Cognitive Impairment (naMCI, n = 16).
TABLE 7 | Prevalence of pathological MRI scores and their statistical characteristics according to diagnosis.







MTA (%) 3(6%) 21(41%) 0.000 19(54%) 2 (12,5%) 0.006
PA (%) 10(20%) 13(25%) 0.477 9(26%) 4(25%) 0.957
GCA-F (%) 4(7%) 7(14%) 0.338 7(20%) 0(0%) 0.054
Fazekas Dicom (SD) (%) 10(20%) 13(25%) 0.477 9(26%) 4(25%) 0.957
# N with pathological score (%) 17(33%) 31(61%) 0.010 25(71%) 6(37.5%) 0.031
# N with ≥ 2 pathological scores (%) 7(13%) 16(31%) 0.057 13(37%) 3(18%) 0.329
MRI SCORING SYSTEMS/CHAR:
MTA combined mean (SD) 0.314(0.469) 0.902(0.860) 0.000 1.04(0.915) 0.594(0.66) 0.054
PA mean(SD) 0.94(0.732) 1.04(0.732) 0.776 0.97(0.568) 0.69(0.704) 0.776
GCA-F mean (SD) 0.71(610) 0.75(0.688) 0.761 0.91(0.702) 0.38(0.500) 0.002
Fazekas (SD) 1.14(0.722) 1.23(0.690) 0.398 0.94(0.772) 1.02(0.678) 0.184
Prevalence group difference significance by Chi Square, Mean difference by two tailed independent sample T-test.
MCI, Mild cognitive impairment, aMCI, amnestic MCI, naMCI, nonamnestic MCI, MTA, Medial temporal lobe atrophy score; GCA-F, Global cortical atrophy score—Frontal subscore;
PA, Koedam score for parietal atrophy. Significant p-values (p < 0.05) in bold.
2014; Beaty et al., 2015; Crittenden et al., 2015; Brown et al.,
2017; Filippi et al., 2017). The lack of correlation between the
GCA-F scores and the executive function domain may also be
due to the fact that some executive function tests have high
sensitivity for assessing brain injury, but may have low specificity.
Damage to a wide variety of brain regions may affect executive
function test performance while isolated frontal damage may
not always result in deficits in executive function that can be
detected by tests (Mesulam, 1998; Strauss et al., 2006; Hestad
and Egeland, 2010; Lezak, 2013). Furthermore, in our MCI
patients, the scores on the working memory domain correlated
inversely with the parietal lobe atrophy score. This finding is
similar to a previous study that found decreased connectivity
between the prefrontal cortex and posterior parietal regions in
early onset AD (Filippi et al., 2017). Atrophy of parietal regions
is also correlated with reduced working memory function in
functional MRI (fMRI) studies of healthy controls (Honey et al.,
2002). PA score on structural MRI may be a useful indicator
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TABLE 8 | Correlations between MRI scores and cognitive domains Z-scores in MCI patients.
Domain name/ radiological score MTA PA Fazekas GCA-F
Attention domain p(CI95) 0.565(−0.319–0.176) 0.231(−0.455–0.087) 0.377(−0.477–0.172) 0.159(−0.553–0.093)
R² 0.019 0.042 0.029 0.053
Processing speed domain p(CI95) 0.157(−0.757– 0.126) 0.778(−0.450–0.597) 0.573(−0.725–0.406) 0.094(−0.088–1.076)
R² 0.088 0.050 0.012 0.104
Working memory domain p(CI95) 0.139(−0.521–0.075) 0.043(–0.690– – 0.011) 0.759(−0.443–0.325) 0.093(−0.729–0.059)
R² 0.069 0.106 0.026 0.081
Episodic learning/short delay recall domain p(CI95) 0.105(−0.623–0.061) 0.247(−0.637–0.168) 0.832(−0.489–0.395) 0.036(–0.924– – 0.031)
R² 0.065 0.039 0.005 0.100
Episodic memory/long delay recall domain p(CI95) 0.043(–0.706–−0.011) 0.355(–0.612–0.224) 0.659(−0.556–0.335) 0.072(−0.896–0.040)
R² 0.100 0.035 0.022 0.084
Executive function domain p(CI95) 0.876(−0.113–0.132) 0.224(−0.226–0.054) 0.787(−0.175–0.133) 0.662(−0.127–0.199)
R² 0.006 0.036 0.007 0.009
MTA, Scheltens Middle temporal lobe atrophy score, Fazekas White matter hyperintensity score. (Fazekas score). Average Frontal subscore of Global Cortical Atrophy score (GCA-F).
Posterior atrophy score (PA). CI(95%) for Beta. Domain Z scores are composed from a mean score from the respective domain scores. Linear regression analyses were performed with
age and sex as covariates. Significant p-values (p < 0.05) in bold.
of reduced working memory function in MCI patients. Since
the PA score may be more readily used in clinical settings than
fMRI and semi-automated morphometric analyses, it may be
a convenient tool for clinicians as an objective biomarker to
corroborate with neuropsychological assessment of the patients’
working memory function. The lack of correlation between the
Fazekas score and any neuropsychological domain scores in our
MCI patients may be a result of theminimal regional information
included in the Fazekas rating scale. The literature regarding
WMH and their relationship to neuropsychological domains
remains somewhat controversial. Some studies have reported
that a greater white matter hyperintensity frequency is associated
with poorer executive function and/or slower processing speed
(Tullberg et al., 2004; Prins and Scheltens, 2015). Other studies
have reported a lack of domain-specific relationship, but found
an impact on global cognition (Overdorp et al., 2014).
STRENGTHS AND LIMITATIONS
A strength of this study is that the study sample is well-defined,
consisting of patients diagnosed in hospital-based Memory
clinics by experienced multidisciplinary teams using national
assessment guidelines. Furthermore, we matched the groups
on SES in addition to age and sex. We used three scales
for the brain MRI measures that took in to consideration
both neurodegenerative and vascular factors. We included
comprehensive neuropsychological assessment in order to cover
all major neuropsychological domains, administrated by the
same experienced neuropsychologist. The MRI scoring was
performed by two experienced radiologists blinded to the group
adherence and viewing the images independently and had
consensus ratings when discrepancies occurred. A limitation
is that the study population is small; therefore the results
should be interpreted with caution. As such, nonsignificant
group differences may be due to insufficient power from the
relatively small sample size. Low specificity and high sensitivity
of the neuropsychological tests may have impacted the lack




Intelligence emerges as a strong covariate in the analyses of
group differences in the cognitive profiles. Based on our data,
we consider GAI useful as an operationalization of the general
cognitive function criteria of MCI. Further, applying the GAI in
general clinical assessments of MCI patients may be helpful in
the diagnostic process to reduce the risk of false positive or false
negative diagnosis by relating the neuropsychological test results
to each individual’s GAI-result before confirming the diagnosis of
MCI.
The tests less influenced by GAI in our study were the
tasks within the verbal episodic learning and memory domain,
and a verbal fluency (categorizing) task within the executive
function domain. Patients with the amnestic MCI subtype was
expected to have poorer cognitive outcomes. In this material their
neuropsychological profiles emerged as significantly impaired in
multiple cognitive domains compared to the nonamnestic MCI
patients.
Our findings may suggest that neuropsychological tests and
the MRI rating scores measure different aspects of the MCI
condition. Also, patients with MCI is a heterogeneous group that
have a variety of reasons for their cognitive impairment, and the
impairment do not necessarily have a structural brain correlate.
However, the usefulness of the MRI rating scores, except for the
MTA scores, appears to be low in identifying an MCI condition.
In older adults with MCI, a pathological MTA score suggests that
the patient should be further assessed for MCI. However, a MTA
score within the normal range does not exclude MCI.
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